CLOs on the Move

Cleveland Biolabs

www.cbiolabs.com

 
Cleveland BioLabs, Inc. (NASDAQ: CBLI) is an innovative bio pharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Our proprietary platform of toll-like immune receptor activators has applications in radiation mitigation, oncology immunotherapy, and vaccines. We combine our proven scientific expertise and our depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our proprietary drug candidates act via unique mechanisms that are designed to kill cancer and protect healthy cells. Our most advanced product candidate is entolimod, which we are developing as a radiation countermeasure and ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cbiolabs.com
  • 73 High St
    Buffalo, NY USA 14203
  • Phone: 716.849.6810
  • Fax: 716.849.6820

Executives

Name Title Contact Details

Similar Companies

Evans Analytical Group LLC

Evans Analytical Group (EAG) has been a global leader in surface analysis and materials characterization for over 29 years, delivering innovative analytical services and solutions with uncompromising scientific integrity.

Rice Home Medical

Rice Home Medical is a Willmar, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Aegis Living

Áegis Living is a national leader in assisted living and memory care. Providing the finest in senior lifestyle and living options, “We`re the people who make life better” emphasizes health, quality of life, well-being and community. Founded in 1997 and headquartered in Redmond, WA, privately-held Áegis Living operates 30 communities in Washington, California and Nevada, with five currently in development.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.